A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open label study of dovitinib in patients with
progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC). The primary purpose
of this study is to assess the anti-cancer effects of dovitinib in this population in order
to evaluate whether dovitinib is worthy of further study in patients with progressive ACC.